<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00775073</url>
  </required_header>
  <id_info>
    <org_study_id>CRAD001C24100</org_study_id>
    <nct_id>NCT00775073</nct_id>
  </id_info>
  <brief_title>Antiangiogenic Treatment of Hepatocellular Cancer With Bevacizumab and RAD001</brief_title>
  <official_title>Antiangiogenic Treatment of Advanced or Metastatic Hepatocellular Cancer (HCC) - An Open Label, Stratified, Single-arm Phase II Study of Bevacizumab and RAD001</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gerhard Treiber</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Crolll Gmbh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Estimate, GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Janssen Diagnostics, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Treiber, Gerhard</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective open label clinical trial in patients with advanced or metastatic liver
      cancer to assess the clinical and biological activity of RAD001 (Everolimus) in conjunction
      with Bevazicumab (Avastin). Approximately 36 patients will be enrolled.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>24 and 48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>24 and 48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevacizumab (Avastin) &amp; Everolimus (RAD001)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus, Bevacizumab</intervention_name>
    <description>Everolimus 5 mg tablet per day orally. Bevazicumab 5 mg per kg intravenous every 2 weeks.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>RAD001</other_name>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18 years

          -  Patients with non-resectable locally advanced or metastatic hepatocellular cancer BCLC
             stage B and C. BCLC stage A can occasionally be included provided that other treatment
             options are unavailable

          -  Measurable disease: At least one measurable lesion (longest diameter ≥20 mm on
             conventional CT or MRI scan; ≥ 10 mm on spiral CT) according to RECIST criteria that
             has not been previously locally treated by irradiation, surgery, ethanol injection,
             radiofrequency ablation or transarterial chemoembolisation

          -  Confirmation of HCC disease by histology (preceding liver resection or fine needle
             biopsy within the last 12 months);

          -  Liver Function: Child A and B

          -  Tumor extent: CLIP Score ≤ 3

          -  ECOG Performance Status 0-2 (=Karnofsky-Index ≥ 60%)

        Exclusion Criteria:

          -  Patient had received any prior systemic treatment (possible exception: sorafenib for a
             maximum of 3 months, last dose received at least 28 days before study inclusion)

          -  Patient had a major surgery, local ablative treatments (RFA, PEI), or transarterial
             chemoembolisation therapy within 4 weeks prior to randomisation

          -  Presence of a secondary malignancy either at the time of screening or in the past 5
             years: An exception from this rule can be made in patients that were treated in
             curative intention within the last 3 years and are without any evidence of recurrence
             of this malignancy.

          -  History or presence of central nervous system (CNS) disease (i.e., primary brain
             tumor, malignant seizures, CNS metastases or carcinomatous meningitis) or other mental
             illness.

          -  Clinically serious infections or uncontrolled infection (including HIV infection),
             increased risk for acquisition of opportunistic infections

          -  Chronic treatment with systemic steroids or another immunosuppressive agent

          -  Inadequate organ functions, characterised by: cholestasis with elevated levels of
             bilirubin and/or alkaline phosphatase &gt; 3x UNL (can be improved by biliary drainage if
             necessary) and/or elevated transaminases (ALAT/ASAT) ≥ 5 x UNL, hypoalbuminemia &lt; 2.5
             g/dl, renal impairment (serum creatinine &lt; 1.5 x UNL ), inadequate Hematology:
             Platelets &lt; 75.000, ANC &lt; 1500, hemoglobin &lt; 9.0 mg/dl, inadequate coagulation status,
             namely INR &gt; 2 or Quick &lt; 50%, aPTT &gt;50 sec in the absence of any drugs interfering
             with coagulation such as warfarin, phenprocoumon, NMH or UFH. Fasting serum
             cholesterol ≤300 mg/dL OR 7.75 mmol/L AND fasting triglycerides ≤ 2.5 x ULN, patients
             with severe refractory therapy-resistant hyperlipidemia

          -  Women who are pregnant or breast feeding, intended pregnancy, or women unable to
             conceive and unwilling to practice an effective method of birth control

          -  Impairment of gastrointestinal (GI) function or GI disease that may significantly
             alter the absorption of RAD001 and cannot be controlled by adequate medical treatment
             (e.g. uncontrolled nausea, vomiting, diarrhoea which might result in malabsorption,
             any known malabsorption syndrome, bowel obstruction, or inability to swallow the
             capsules/tablets)

        Exclusion Criteria derived from special situations:

          -  Mixed tumors of HCC with cholangiocarcinoma or fibrolamellar HCC type

          -  Patients with complications of liver cirrhosis such as recent spontaneous bacterial
             infection of ascites, hepatic encephalopathy &gt; grade 2 during the last 2 weeks and not
             adequately controlled or hepatorenal syndrome not responding to conservative treatment
             within 2 weeks

          -  Patients with any active gastrointestinal bleeding during the last 2 weeks

          -  Patients without screening EGD during the last 2 weeks

          -  Patients with nonbleeding gastroesophageal varices grade I° with red coloured signs or
             grade ≥ II° on EGD that do not undergo prophylactic ligation or sclerosing treatment
             at least one week before the first dose of study medication is taken.

          -  Patients with unhealed gastrointestinal ulcerations or wounds

          -  Patients with a history of one of the following: bowel perforation, colon
             diverticulitis

          -  Any relevant findings on screening colonoscopy

          -  History of any thromboembolic events (except for portal vein infiltration and/or
             thrombosis)

          -  Allergic reactions or intolerance to previous drug exposure to RAD001 or bevacizumab;
             having received any of the study medications within the last 3 years before
             randomisation

          -  Allergy or intolerance against CHO-cell products or other recombinant human or
             humanised antibodies

          -  Patients with an increased risk for the development of lymphoma or other malignant
             diseases, especially concerning the skin

          -  Patients with rare hereditary disorders like galactose intolerance, lactase deficiency
             or glucose-galactose malabsorption
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerhard Treiber, PD Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zollernalbklinikum Balingen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medizinische Klinik 1 University of Erlangen</name>
      <address>
        <city>Erlangen</city>
        <state>Bavaria</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zollernalbklinikum</name>
      <address>
        <city>Balingen</city>
        <zip>72336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité, Campus Virchow Klinikum, Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Bonn, Medizinische Klinik und Poliklinik I</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der J.-W.-Goethe-Universitaet, Medizinische Klinik I</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitaetsklinik Freiburg, Innere Medizin II</name>
      <address>
        <city>Freiburg</city>
        <zip>79095</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martin-Luther-Universitaet Halle-Wittenberg, Universitaetsklinik und Poliklinik für Innere Medizin I</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover, Zentrum Innere Medizin</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlandes Klinik für Innere medizin II</name>
      <address>
        <city>Homburg/Saar</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Fakultaet der Otto-von-Guericke-Universitaet, Klinik für Gastroenterologie, Hepatologie und Infektiologie</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2008</study_first_submitted>
  <study_first_submitted_qc>October 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2008</study_first_posted>
  <last_update_submitted>April 27, 2012</last_update_submitted>
  <last_update_submitted_qc>April 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Treiber, Gerhard</investigator_affiliation>
    <investigator_full_name>Gerhard Treiber</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>Liver cancer</keyword>
  <keyword>HCC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Angiogenesis Inhibitors</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

